TB-500, a synthetic version of Thymosin Beta-4, is primarily explored in our corpus for its potential in regenerative medicine, sports recovery, and orthopaedic repair, with evidence suggesting its ability to accelerate healing, reduce inflammation, and promote tissue regeneration. Thymosin Alpha-1, an immunomodulatory peptide, has a broader therapeutic landscape in our indexed studies, showing significant efficacy as an adjunctive therapy in conditions such as HBV-related cirrhosis, acute exacerbations of COPD, and particularly in improving outcomes for adult COVID-19 patients by reducing mortality and the need for mechanical ventilation. Both peptides are subjects of ongoing research into their therapeutic applications.
| TB-500 | Thymosin Alpha-1 | |
|---|---|---|
| Drug class | healing peptide, thymosin | thymosin, immune modulator |
| Studies in corpus | 17 | 147 |
| Highest evidence tier | review | meta analysis |
| Evidence tier mix | review · 6 in vitro · 3 other · 6 preclinical animal · 2 | other · 48 rct · 40 preclinical animal · 13 in vitro · 12 case series · 8 cohort · 6 meta analysis · 7 review · 7 case report · 4 |
| Studies with explicit sample size | 0 | 17 |
| Head-to-head studies in corpus | 2 | |
Studies in our corpus that mention both TB-500 and Thymosin Alpha-1 — the gold-standard direct comparison evidence.
This robust and expanding patenting activity unequivocally underscores the escalating commercial and clinical interest in thymosin peptides as a promising class of therapeutics. The identification of rapidly emerging therapeutic areas, particularly in oncol…
No direct head-to-head trials in our corpus. Indirect comparison only. While both peptides are subjects of growing interest, their primary therapeutic applications, based on the studies indexed here, diverge significantly. TB-500 is predominantly studied for its roles in tissue repair and regeneration, particularly in orthopaedic contexts and sports recovery, with reviews highlighting its potential to combat age-related diseases and its detection in anti-doping efforts. Thymosin Alpha-1, in contrast, shows strong evidence as an immunomodulator, with multiple meta-analyses supporting its use in infectious diseases like COVID-19 to improve critical clinical outcomes and in chronic conditions such as HBV-related cirrhosis and COPD exacerbations to enhance standard care. The corpus for Thymosin Alpha-1 is substantially larger (164 studies) and includes more meta-analyses than for TB-500 (19 studies), suggesting a greater depth of clinical evidence for Thymosin Alpha-1 in its indicated areas based on the studies indexed here.
Looking for vendor-level purity, endotoxin, and HPLC data on TB-500 or Thymosin Alpha-1? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.